

University of Groningen

Novel therapies in heart failure

Liu, Licette Cécile Yang

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2016

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Liu, L. C. Y. (2016). *Novel therapies in heart failure*. Rijksuniversiteit Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

STELLINGEN

Novel Therapies in Heart Failure

1. Serelaxin has a greater treatment benefit in acute heart failure patients with renal impairment compared to acute heart failure patients without renal impairment. *(This thesis)*
2. Even in a neutral study, there might be a group of patients that either benefits from or is harmed by treatment. *(This thesis)*
3. Plasma biomarkers may be useful tools to distinguish responders from non-responders. *(This thesis)*
4. Although treatment with LCZ696 preserves renal function in patients with heart failure with preserved ejection fraction, it increases urinary albumine creatinine ratio, compared with valsartan. *(This thesis)*
5. Sildenafil has no added value in the treatment of patients with heart failure with preserved ejection fraction and predominantly post-capillary pulmonary hypertension. *(This thesis)*
6. Due to its pharmacokinetic and pharmacodynamic characteristics, finerenone can become the third generation mineralocorticoid receptor antagonist. *(This thesis)*
7. Unlike current cornerstone heart failure therapy, omecamtiv mecarbil directly improves cardiac function. *(This thesis)*
8. One size does not fit all.
9. It's more important to know what sort of person has a disease than to know what sort of disease a person has. *(Hippocrates)*
10. Tegenwind houdt je hoofd fris.
11. Door bergen te beklimmen, kun je ver kijken.
12. Als je alleen achterom kijkt, kom je nooit vooruit.
13. Liefde maakt elke afstand significant korter.